- The program focuses on the pursuit of reduced risk oral nicotine products that make use of Lexaria’s patented DehydraTECH drug delivery platform
- DehydraTECH has been studied extensively and both human/animal trials confirm its ability to enhance active ingredient absorption in digestible products
- The current research could contribute to the development of oral nicotine products that would usher in a new era of reduced-risk nicotine use
Global innovator in drug delivery platforms Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) provided an extensive update on advances in its research and development program with Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc (NYSE: MO). The collaboration focuses on the pursuit of reduced risk oral nicotine consumer products using the Lexaria-patented DehydraTECH technology.
Most of the work within the first phase of the collaborative project has either been completed or is significantly underway. Only one aspect of the project remains to commence imminently, according to a company press release issued on October 8, 2019 (http://ibn.fm/Czxkv).
The successful completion of the first phase of the program will be the first step in developing viable products with Lexaria’s DehydraTECH drug delivery platform. Under the terms and conditions of the agreement, Lexaria’s majority owned subsidiary Lexaria Nicotine LLC will see royalties being paid from any sold oral nicotine products, in the event of Altria deciding to use the technology in the U.S. or overseas.
Due to the advances in the program, the two partners have been thoroughly studying the process of oral nicotine administration. Lexaria Bioscience and Lexaria Nicotine CEO Chris Bunka said, “Lexaria strongly believes that, given the choice, many of the world’s one billion smokers would elect to experience their nicotine in a manner that does not rely on either smoking or vaping, and Lexaria can help enable these alternatives.”
Lexaria’s philosophy is that the oral administration of nicotine can provide a reduced-risk access to the substance, providing better health outcomes than standard combustible cigarettes.
The DehydraTECH technology is a vital component for product development. Human and animal clinical studies have demonstrated DehydraTECH’s ability to enhance bio-absorption and bioavailability of active compounds in oral administration products.
The technology has a wide scope of additional applications. DehydraTECH can improve taste, remove odor and bring down the time to onset in the case of delivering active ingredients within generally recognized as safe (GRAS) food ingredients. Because of its superior performance characteristics, the technology is also being used by the CBD industry. Research suggested that CBD absorption into human intestinal cells increased by 499 percent through the utilization of the DehydraTECH technology.
Similar results were observed in previous animal studies, suggesting a massive increase in absorption (811 percent) when comparison was made with a control group.
Lexaria has also completed several phases of collaborative study with the National Research Council in Canada (http://ibn.fm/UC2eZ). Several work programs were designed to evaluate and characterized the DehydraTECH technology utilizing nuclear magnetic resonance and other advanced methods of study such as DLS and Zeta Potential analysis.
Lexaria Bioscience is a global innovator in drug delivery platforms. It operates a licensed in-house research laboratory and the company also holds an impressive portfolio of 16 patents granted and over 60 patents pending.
For more information, visit the company’s website at www.LexariaBioscience.com
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP